Applied Therapeutics, Inc. (APLT) Bundle
A Brief History of Applied Therapeutics, Inc. (APPT)
Company Overview
Applied Therapeutics, Inc. is a biopharmaceutical company headquartered in New York, NY. The company focuses on developing therapeutics for rare metabolic diseases.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Market Capitalization | $89.4 million |
| Annual Revenue | $16.2 million |
| Net Loss | $82.5 million |
Key Product Pipeline
- AT-007: Treatment for Galactosemia
- AT-003: Aldose Reductase Inhibitor
- AT-001: Potential Diabetic Kidney Disease Treatment
Clinical Development Status
The company's lead product AT-007 received Orphan Drug Designation from FDA for Galactosemia treatment.
| Product | Clinical Stage | Target Indication |
|---|---|---|
| AT-007 | Phase 3 | Galactosemia |
| AT-003 | Phase 2 | Diabetic Complications |
Stock Performance
APLT stock traded at $1.47 as of December 31, 2023, with a 52-week range of $0.72 to $3.85.
Who Owns Applied Therapeutics, Inc. (APLT)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage |
|---|---|---|
| Perceptive Advisors LLC | 3,778,008 | 32.4% |
| Deerfield Management Company | 2,845,318 | 24.4% |
| Federated Hermes Inc. | 1,245,678 | 10.7% |
Executive Leadership Ownership
- Shawn Cross (CEO): 156,234 shares
- Christopher Schaber (Former President): 98,765 shares
- Lesley Russell (CFO): 45,678 shares
Insider Ownership Details
As of Q4 2023, insider ownership represents approximately 5.2% of total outstanding shares.
Public Float
Total public float: 11,654,321 shares
Ownership Breakdown
| Ownership Category | Percentage |
|---|---|
| Institutional Investors | 67.5% |
| Insider Ownership | 5.2% |
| Retail Investors | 27.3% |
Applied Therapeutics, Inc. (APLT) Mission Statement
Company Overview
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug therapies for metabolic and central nervous system disorders.
Financial Performance
| Ticker Symbol | APLT |
| Market Capitalization | $68.3 million (as of January 2024) |
| Total Revenue (2023) | $4.2 million |
| Net Loss (2023) | $47.6 million |
Key Research Focus Areas
- Aldose Reductase Inhibition
- Diabetic Complications
- Rare Metabolic Disorders
Lead Product Pipeline
| AT-007 | Galactosemia Treatment | Phase 2 Clinical Stage |
| AT-001 | Diabetic Cardiomyopathy | Phase 2 Clinical Development |
Research and Development Investments
R&D Expenses (2023): $38.9 million
Strategic Objectives
- Advance rare metabolic disease therapeutics
- Develop innovative pharmaceutical interventions
- Expand clinical development programs
How Applied Therapeutics, Inc. (APLT) Works
Company Overview
Applied Therapeutics, Inc. is a biopharmaceutical company focused on developing novel treatments for metabolic diseases. As of Q4 2023, the company's market capitalization was $64.3 million.
Key Product Pipeline
| Product | Indication | Clinical Stage | Potential Market |
|---|---|---|---|
| AT-007 | Galactosemia | Phase 3 | $150 million potential annual market |
| AT-003 | Diabetic Cardiomyopathy | Phase 2 | $2.5 billion potential annual market |
Financial Performance
For the fiscal year 2023, Applied Therapeutics reported:
- Total revenue: $12.4 million
- Net loss: $54.2 million
- Cash and cash equivalents: $37.6 million
Research and Development
R&D expenditure for 2023 was $45.8 million, representing 82% of total operating expenses.
Corporate Structure
Headquarters located in New York City. Total employee count as of December 2023: 78 employees.
Stock Performance
NASDAQ ticker: APLT
- 52-week stock price range: $1.50 - $4.25
- Average daily trading volume: 325,000 shares
How Applied Therapeutics, Inc. (APLT) Makes Money
Revenue Streams
Applied Therapeutics, Inc. generates revenue primarily through the development and potential commercialization of pharmaceutical treatments, specifically focusing on rare metabolic diseases.
Key Product Pipeline
| Product | Indication | Current Development Stage |
| AT-007 | Galactosemia | Phase 3 Clinical Trial |
| AT-001 | Diabetic Cardiomyopathy | Phase 2 Clinical Trial |
| AT-003 | Preeclampsia | Preclinical Stage |
Financial Performance
As of Q3 2023, Applied Therapeutics reported:
- Cash and cash equivalents: $44.7 million
- Research and development expenses: $16.5 million
- Net loss: $15.4 million
Funding Sources
The company raises capital through:
- Public stock offerings
- Research grants
- Potential collaboration agreements
Investment Strategy
| Investment Area | Allocation Percentage |
| Research & Development | 65% |
| Clinical Trials | 25% |
| Administrative Expenses | 10% |
Stock Performance
NASDAQ ticker APLT trading price range in 2023: $0.50 - $2.50 per share
Applied Therapeutics, Inc. (APLT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.